Addiction

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

SEATTLE and VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical…

12 months ago

Digital Safety Alliance Marks One-Year Anniversary with the Launch of Digital Safety Virtual Assistant

MIAMI, Feb. 10, 2025 /PRNewswire/ -- The Digital Safety Alliance (DSA) is proud to celebrate its one-year anniversary with the…

12 months ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2…

12 months ago

Lightning Step Appoints Josh Steinbaum as New Chief Financial Officer

HOUSTON--(BUSINESS WIRE)--Lightning Step, a leading provider of integrated CRM, EHR, and RCM solutions for behavioral health practices, has appointed Josh…

12 months ago

Lightning Step Appoints Josh Steinbaum as New Chief Financial Officer

HOUSTON--(BUSINESS WIRE)--Lightning Step, a leading provider of integrated CRM, EHR, and RCM solutions for behavioral health practices, has appointed Josh…

12 months ago

TreatmentRehabCenters.org Launches New Platform Highlighting the Best Rehab Centers for 2025

Top Treatment Centers Across the USA: Vetted by Experts to Support Recovery Success BOSTON, Jan. 30, 2025 /PRNewswire/ -- TreatmentRehabCenters.org,…

1 year ago

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is…

1 year ago

Global Wellness Summit Releases 10 Wellness Trends for 2025

In a polarized wellness market, we'll see both "analog wellness" (a great logging off and seizing of pre-digital experiences) and…

1 year ago

Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD

Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn"…

1 year ago

Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

Pain marks the second therapeutic area for Cullgen’s lead protein degrader CG001419SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen…

1 year ago